Nektar Therapeutics
| Formerly | Inhale Therapeutic Systems, Inc. |
|---|---|
| Company type | Public |
| Industry | Biopharmaceuticals |
| Founded | 1990 |
| Headquarters | San Francisco, California, U.S. |
| Products | |
| Revenue | US$90.1million (2023) |
Number of employees | 137 (2024) |
| Website | nektar |
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.